Search Results
Your search for all items matches 34420 pages
Showing 1 - 50
Kristina Maas-Bauer, MD, on ROCK1/2 Inhibition and GVHD
Kristina Maas-Bauer, MD, of the University of Freiburg, discusses preclinical research on the role of ROCK1/2 in graft-vs-host disease (GVHD), which found an effect on myeloid cells, both in phenotype profile and migration capabilities. Additionally, she discusses the potential of combining ROCK1/2 ...
Neeraj Agarwal, MD, FASCO, on mCRPC: Talazoparib Plus Enzalutamide as First-Line Treatment
Neeraj Agarwal, MD, FASCO, of Huntsman Cancer Institute, presents data from cohort 1 of the phase III TALAPRO-2 trial—final overall survival data, an update on radiographic progression–free survival, and safety follow-up—which included patients with metastatic castration-resistant prostate cancer...
Karim Fizazi, MD, PhD, on HRR-Deficient mCRPC: Final Overall Survival in TALAPRO-2
Karim Fizazi, MD, PhD, of Institut Gustave Roussy, University of Paris-Saclay, reviews final overall survival results from cohort 2 of the phase III TALAPRO-2 trial, which investigated the combination of talazoparib and enzalutamide in patients with homologous recombination repair (HRR)-deficient...
Betty Hamilton, MD: Research Highlights in GVHD
Betty Hamilton, MD, of Cleveland Clinic, outlines key data from a clinical session she co-chaired on graft-vs-host disease (GVHD), including the role of JAK inhibitors in the prevention of the condition and novel therapies for the management of acute GVHD.
William Aronson, MD, on a Specialized Diet in Men on Active Surveillance for Prostate Cancer
William Aronson, MD, of the VA Greater Los Angeles Healthcare System, discusses findings from the CAPFISH-3 trial, which investigated whether a high omega-3, low omega-6 fatty acid diet with fish oil capsules decreased Ki-67 levels in men with prostate cancer on active surveillance (Abstract 312).
Influencing Geriatric Oncology Practice Worldwide: 2024 International Society of Geriatric Oncology Conference
The Annual Meeting of the International Society of Geriatric Oncology (SIOG) was held from October 17–19, 2024, in Montreal. The conference theme was “Promoting Equity and Enhancing Optimal Care Delivery.” The conference chairs were Shabbir Alibhai, MD, MSc, FRCPC, and Martine Puts, RN, PhD, FAAN,...
Genetic Testing May Identify High-Risk Cytogenetic Abnormalities in Patients With Multiple Myeloma
Offering genetic testing to patients with multiple myeloma may help physicians to determine which patients have the most aggressive types of the disease and how to target their malignancy more effectively, according to a recent study published by Kaiser et al in the Journal of Clinical Oncology....
Adding Tumor Deposit Status to Cancer Staging May Improve Prognostication in Colorectal Cancer
Investigators assessed whether adding tumor deposit status to colorectal cancer staging may enhance prognostication, according to a recent study published by Sassun et al in JAMA Surgery. Background In patients undergoing surgical treatment of colorectal cancer, tumor deposits are defined as...
Locally Advanced Gastric Cancer: Adjuvant or Perioperative Therapy With D2 Resection
As reported in The Lancet Oncology by Zhang et al, final outcomes of the Chinese phase III RESOLVE trial showed improved overall survival with adjuvant S-1 and oxaliplatin (SOX) and perioperative SOX vs adjuvant capecitabine/oxaliplatin (CapOx) in patients with locally advanced gastric or...
Novel CD19-1XX CAR With Calibrated Signaling in LBCL
In a single-institution phase I study reported in the Journal of Clinical Oncology, Jae H. Park, MD, and colleagues found that first-in-human use of a CD19-1XX chimeric antigen receptor (CAR) T-cell therapy with calibrated signaling showed high activity in patients with relapsed or refractory large ...
Masood Moghul, PhD, on a Mobile Prostate Cancer Clinical Unit: Findings From the Man Van
Masood Moghul, PhD, of The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, describes the impact of a nurse-led mobile clinical unit on targeted screening invitations to men at high risk for prostate cancer in disadvantaged communities in London (Abstract 317).
Omid Yazdanpanah, MD, on Metastatic Castration-Resistant Prostate Cancer: LuPSMA With or Without ARPIs
Omid Yazdanpanah, MD, of the University of California, Irvine, presents findings from a secondary analysis of the VISION trial, which compared the efficacy and safety of LuPSMA in patients treated with vs without concomitant androgen receptor pathway inhibitors (ARPIs) (Abstract 121).
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
“Care more particularly for the individual patient than for the special features of the disease.”—Sir William Osler Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment are older than ...
Combination Immunotherapy Plus Radiotherapy in Muscle-Invasive Bladder Cancer
Studies show that although radical cystectomy has long been recognized as the standard-of-care for localized muscle-invasive bladder cancer (MIBC), the surgery carries significant morbidity and the risk of subsequent loss of quality of life for patients. Preclinical studies have suggested that a...
Pembrolizumab in Previously Treated Advanced Clear Cell Gynecological Cancers
As reported in JAMA Oncology by Kristeleit et al, the UK-based phase II PEACOCC trial has shown the benefit of pembrolizumab in previously treated patients with advanced clear cell gynecological cancers (CCGCs). As stated by the investigators, “Advanced CCGCs have a poor prognosis, with response...
Racial, Ethnic Disparities in Diagnostic Procedures Following Abnormal Mammograms
Investigators may have uncovered racial and ethnic disparities in the receipt of same-day diagnostic services and biopsies following abnormal mammogram findings in spite of the similar availability of diagnostic technologies, according to a recent study published by Lawson et al in Radiology....
Safety of Ceasing Combination Therapy After 2 Years in Patients With Renal Cell Carcinoma
Ceasing or pausing a combination of the immune checkpoint inhibitor nivolumab and the oral tyrosine kinase inhibitor (TKI) axitinib after 2 years may be safe among patients with metastatic renal cell carcinoma who achieved a positive response to this treatment, according to updated analysis of a...
Untreated CLL: Acalabrutinib Combinations vs Chemoimmunotherapy
As reported in The New England Journal of Medicine by Jennifer Brown, MD, and colleagues, the phase III AMPLIFY trial found that fixed-duration acalabrutinib combined with venetoclax or venetoclax/obinutuzumab improved progression-free survival vs chemoimmunotherapy in fit, previously untreated...
Cancer, Aging, and Meaning: Navigating Psychosocial Challenges
I’ve learned a lot about medicine over the years, but one thing I wasn’t taught was how to guide someone through the existential weight of dying. My education centered on diagnosing, curing, or at least managing disease—not on the delicate art of helping people and their loved ones cope with what...
Vimseltinib Approved by the FDA for Symptomatic TGCT
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. MOTION Trial Efficacy was...
Mantle Cell Lymphoma: Addition of Venetoclax to Ibrutinib
As reported in The Lancet Oncology by Michael Wang, MD, and colleagues, the phase III SYMPATICO trial has shown that venetoclax/ibrutinib significantly improved progression-free survival vs placebo/ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL). Study Details In the...
Merkel Cell Carcinoma: Nivolumab With or Without Ipilimumab in Recurrent or Metastatic Disease
As reported in the Journal of Clinical Oncology by Bhatia et al, nivolumab/ipilimumab did not produce better outcomes vs nivolumab alone in a cohort of immune checkpoint inhibitor (ICI)-naive patients with recurrent or metastatic Merkel cell carcinoma (MCC) enrolled in the phase I/II CheckMate 358...
Comprehensive CT Scans May Help to Identify Atherosclerosis Among Patients With Lung Cancer
Several cardiovascular risk factors such as advanced age and smoking history may be prevalent among patients with lung cancer at the time of diagnosis and may increase their risk of future cardiovascular disease, according to findings presented by Malozzi et al at the American College of...
Are Immune Checkpoint Inhibitors Effective in Hospitalized Patients With Cancer?
Immune checkpoint inhibitors may be ineffective among patients hospitalized with cancer, according to a recent study published by Riaz et al in JCO Oncology Practice. Background Immune checkpoint inhibitors have transformed treatment for many cancer types but are often restricted for inpatient use...
Flagellin and Immune Checkpoint Inhibition in Patients With Ovarian Cancer
The interference of gut bacteria could explain the ineffectiveness of immune checkpoint therapy in some patients with ovarian cancer, according to a recent study published by McGinty et al in Cancer Immunology Research. Background There are over 10,000 ovarian cancer–related deaths in the United...
Colorectal Cancer Treatment Resistance: Oncofetal Reprogramming
Researchers may have uncovered a major factor contributing to treatment resistance in patients with colorectal cancer, according to a recent study published by Mzoughi et al in Nature Genetics. Background Colorectal cancer is one of the deadliest cancer types across the world, with treatment...
ctDNA and Immunoscore in Resected Stage III Colon Cancer
As reported in the Journal of Clinical Oncology by Taieb et al, a combined analysis of two phase III adjuvant trials (IDEA-France and IDEA-Greece) in stage III colon cancer showed that the presence of circulating tumor DNA (ctDNA) after surgery was prognostic for poorer outcomes and that...
Potential Benefit of Consuming Yogurt in Decreasing the Risk of Certain Types of Colorectal Cancers
Long-term yogurt intake may protect against the development of colorectal cancer through changes in the gut microbiome, according to a recent study published by Ugai et al in Gut Microbes. Background Yogurt—which contains live strains of bacteria—is thought to protect against many types of...
Novel Blood Test May Help to Identify Pancreatic Ductal Adenocarcinoma at an Earlier Stage
A novel blood test may aid physicians in the earlier detection of pancreatic ductal adenocarcinoma and potentially improve survival rates for the disease, according to a recent study published by Montoya et al in Science Translational Medicine. Background Pancreatic ductal adenocarcinoma is the...
Annual vs Less Frequent Mammographic Surveillance in Breast Cancer Patients Aged ≥ 50 Years
In a UK phase III noninferiority trial (Mammo-50) reported in The Lancet, Dunn et al found that less frequent mammographic surveillance was noninferior to annual surveillance in outcomes among patients with breast cancer aged 50 years or older. Study Details In the multicenter trial, 5,235 women...
Association of Acute and Late Toxicity in Radiotherapy for Prostate Cancer
In an individual patient data meta-analysis reported in The Lancet Oncology, Nikitas et al found that early toxicity associated with radiotherapy for prostate cancer was associated with increased risk for late toxicity. Study Details The study included patient-level data from six randomized phase...
Baseline Liquid Biopsy vs Tissue-Based Findings in Metastatic Colorectal Cancer
In an analysis reported in the Journal of Clinical Oncology, Stintzing et al found that baseline liquid biopsies identified RAS and BRAF mutations in patients with metastatic colorectal cancer considered RAS wild-type on the basis of tissue analyses. Study Details The study included patients from...
Final Overall Survival Results From TALAPRO-2 in Unselected Patients With Metastatic Castration-Resistant Prostate Cancer
The final overall survival results from cohort 1 of the phase III TALAPRO-2 trial showed a statistically significant and clinically meaningful improvement with the PARP inhibitor talazoparib plus the androgen receptor inhibitor enzalutamide vs standard-of-care enzalutamide in treatment-naive...
eNRGy Trial: Zenocutuzumab for NRG1 Gene Fusion–Positive Solid Tumors
Treatment with the HER2 × HER3 bispecific antibody zenocutuzumab-zbco appeared to be safe and active in patients with advanced NRG1 gene fusion–positive solid tumors, according to results from the registrational phase II eNRGy study published by Schram et al in The New England Journal of Medicine....
Cancer Mortality Rates Continue to Decline, Incidence Rates in Women Rise, and Racial Disparities Persist
The findings in the American Cancer Society (ACS) annual report, Cancer Statistics, 2025,1 showed a mixed trend in cancer incidence and mortality rates. Although cancer mortality declined by 34% from 1991 to 2022 in the United States—largely because of smoking reductions, earlier detection, and...
Nicholas D. James, PhD, FRCP, MBBS, on an ADT Option: Transdermal Estradiol Patches
Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, discusses findings from an embedded phase II randomized study from the STAMPEDE trial. The study assessed the efficacy and toxicity of transdermal estradiol patches vs...
Talazoparib Plus Enzalutamide Significantly Improves Overall Survival in Prostate Cancer Regardless of HRR Gene Status
Studies show that about one-quarter of advanced prostate cancers have alterations in DNA damage response genes involved directly or indirectly in homologous recombination repair (HRR) gene alterations, including BRCA1/BRCA2 genes, which can sensitize them to treatment with PARP inhibitors. Final...
Benjamin Maughan, MD, PharmD, on Exercise Therapy for Patients With Advanced Prostate Cancer
Benjamin Maughan, MD, PharmD, of Huntsman Cancer Institute, discusses the effects of a 12-week, structured, guided exercise program called Personal Optimism With Exercise Recovery (POWER) on fatigue and peak aerobic exercise capacity in patients with advanced prostate cancer receiving...
Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer
The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E–mutant metastatic colorectal cancer, according to data presented at the 2025 ASCO Gastrointestinal ...
I’m a 2.0 Version of Myself After Cancer
Although there’s no history of breast cancer in my family, when I was 10, my pediatrician introduced me to breast self-exams, so I would become familiar with my breasts and learn to spot any unusual changes as I got older. I remember her telling me this was an especially important exercise to do...
Former UNMC Cancer Center Director, Kenneth H. Cowan, MD, PhD, Dies at 77
Kenneth H. Cowan, MD, PhD, served for 24 years as Director of the National Cancer Institute (NCI)-designated cancer center at the University of Nebraska Medical Center (UNMC), now called the Nebraska Medicine Fred & Pamela Buffett Cancer Center in Omaha. Dr. Cowan died on December 15, 2024, at ...
Felix Feng, MD, Leader in Genitourinary Cancer, Dies at Age 48
NRG Oncology, the RTOG Foundation, and the University of California, San Francisco (UCSF), announced the death of Felix Feng, MD, from cancer at age 48 on December 10, 2024. Dr. Feng was a George and Judy Marcus Distinguished Professor; Professor of Radiation Oncology, Urology and Medicine; Vice...
ARIEL4: Rucaparib vs Chemotherapy for Relapsed Ovarian Cancer With Deleterious BRCA1 or BRCA2 Mutations
In an article in The Lancet Oncology, Oza et al presented the final overall survival analysis of the phase III ARIEL trial of rucaparib vs standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma. Study Details In the open-label trial, 349 patients from sites in 12...
How Telehealth Is Broadening Access to Early Palliative Care and Improving Outcomes for Patients With Advanced Lung Cancer
Although national guidelines, including ASCO’s palliative care guideline,1 call for the early integration of palliative and oncology care for patients with advanced cancer, only 36% of those with a very poor prognosis and 18% of those with a poor prognosis receive palliative care services.2 The...
Primary Analysis of ZUMA-2: Bruton Tyrosine Kinase Inhibitor–Naive Relapsed or Refractory Mantle Cell Lymphoma
ZUMA-2 is a single-arm, multicenter, open-label phase II study that investigated leukapheresed adults with mantle cell lymphoma whose disease was refractory to or had relapsed after up to five prior lines of therapy, including anthracycline or bendamustine-containing chemotherapy; anti-CD20...
WHO, St. Jude Launch New Global Platform to Deliver Cancer Drugs to Pediatric Patients in Low-, Middle-Income Countries
The World Health Organization (WHO) and St. Jude Children’s Research Hospital have begun distributing critical cancer drugs to pediatric patients in two of six pilot countries through the new Global Platform for Access to Childhood Cancer Medicines. Background Every year, about 400,000 children...
ASCO Updates Guidelines on Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
ASCO has updated its guidelines on the role of neoadjuvant chemotherapy for patients newly diagnosed with advanced ovarian cancer, underscoring key considerations in selecting patients for treatment and where to go from there.1 Since ASCO’s previous guidelines were published in 2016, there has been ...
Jennifer A. Woyach, MD, Named The Ohio State’s Director of Hematology
Jennifer A. Woyach, MD, a hematology cancer expert and researcher who has been with The Ohio State for more than 12 years, has been named Director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research...
Intratumoral Injection of mRNA-2752 and Pembrolizumab in High-Risk DCIS
In a single-institution phase I trial reported in JAMA Oncology, Ramalingam et al found that intratumoral injection of pembrolizumab and mRNA-2752 (a combination of interleukin [IL]-23, IL-36γ, and OX40L mRNAs) was active in patients with high-risk ductal carcinoma in situ (DCIS). Study Details Ten ...
